UNSPSC 51383901: Clonixeril

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H17CLN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XVF42I68OX, more generally known as clonixeril. European Medicines Agency schedules clonixeril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06733MIG. The term CLONIXERIL is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, no. 11 1970, list 10.

UNSPSC 51383901 Clonixeril, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single posted opportunity — Seminole County, Florida's IFB60459723LAS — solicits Naloxone and Safe Drug Deactivation Systems, which are opioid-overdose reversal agents and harm-reduction equipment, not clonixeril (an NSAID). The mismatch suggests either a data-coding error in the opportunity posting or a misalignment between the UNSPSC taxonomy assignment and the actual goods being procured. State and local procurement offices do source pharmaceutical products and medical supplies through formal bidding, but the code shows little relevant recent activity tied to its nominal scope.

The single available record reflects Seminole County's need for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (a date inconsistency in the source), required electronic bid submission, fixed unit pricing, drug-free workplace and E-Verify certification, and standard insurance coverages. The contract carried a two-year initial term with one-year renewal option and potential FEMA funding. Without additional opportunities posted under this code in the recent record, no geographic spread or pattern of repeat issuing bodies can be characterized.